BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services fo… Read more
BORA PHARMACEUTICALS LTD (6472) - Net Assets
Latest net assets as of September 2025: NT$15.69 Billion TWD
Based on the latest financial reports, BORA PHARMACEUTICALS LTD (6472) has net assets worth NT$15.69 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$43.74 Billion) and total liabilities (NT$28.05 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$15.69 Billion |
| % of Total Assets | 35.87% |
| Annual Growth Rate | 55.42% |
| 5-Year Change | 509.05% |
| 10-Year Change | N/A |
| Growth Volatility | 37.29 |
BORA PHARMACEUTICALS LTD - Net Assets Trend (2019–2024)
This chart illustrates how BORA PHARMACEUTICALS LTD's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BORA PHARMACEUTICALS LTD (2019–2024)
The table below shows the annual net assets of BORA PHARMACEUTICALS LTD from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | NT$15.01 Billion | +27.59% |
| 2023-09-30 | NT$11.77 Billion | +128.89% |
| 2022-09-30 | NT$5.14 Billion | +63.06% |
| 2021-09-30 | NT$3.15 Billion | +27.90% |
| 2020-09-30 | NT$2.46 Billion | +49.04% |
| 2019-09-30 | NT$1.65 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to BORA PHARMACEUTICALS LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 991.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$6.45 Billion | 50.11% |
| Common Stock | NT$1.03 Billion | 8.03% |
| Other Comprehensive Income | NT$364.57 Million | 2.83% |
| Other Components | NT$5.02 Billion | 39.02% |
| Total Equity | NT$12.87 Billion | 100.00% |
BORA PHARMACEUTICALS LTD Competitors by Market Cap
The table below lists competitors of BORA PHARMACEUTICALS LTD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CP AXTRA PUBLIC THAI NVDR
BK:CPAXT-R
|
$1.04 Billion |
|
SCHOUW A/S DK 10
F:5RF
|
$1.04 Billion |
|
Cibus Nordic Real Estate AB (publ)
ST:CIBUS
|
$1.04 Billion |
|
Elgi Equipments Limited
NSE:ELGIEQUIP
|
$1.04 Billion |
|
Datang HuaYin Electric Power Co Ltd
SHG:600744
|
$1.04 Billion |
|
MVV Energie AG
F:MVV1
|
$1.04 Billion |
|
IHS Holding Ltd
NYSE:IHS
|
$1.04 Billion |
|
dentalcorp Holdings Ltd.
PINK:DNTCF
|
$1.04 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BORA PHARMACEUTICALS LTD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,084,787,000 to 12,867,402,000, a change of 3,782,615,000 (41.6%).
- Net income of 3,939,009,000 contributed positively to equity growth.
- Dividend payments of 1,232,804,000 reduced retained earnings.
- Share repurchases of 389,127,000 reduced equity.
- Other comprehensive income increased equity by 289,915,000.
- Other factors increased equity by 1,175,622,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$3.94 Billion | +30.61% |
| Dividends Paid | NT$1.23 Billion | -9.58% |
| Share Repurchases | NT$389.13 Million | -3.02% |
| Other Comprehensive Income | NT$289.92 Million | +2.25% |
| Other Changes | NT$1.18 Billion | +9.14% |
| Total Change | NT$- | 41.64% |
Book Value vs Market Value Analysis
This analysis compares BORA PHARMACEUTICALS LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 31.32x to 4.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-09-30 | NT$15.37 | NT$481.50 | x |
| 2020-09-30 | NT$21.30 | NT$481.50 | x |
| 2021-09-30 | NT$33.67 | NT$481.50 | x |
| 2022-09-30 | NT$38.27 | NT$481.50 | x |
| 2023-09-30 | NT$73.17 | NT$481.50 | x |
| 2024-09-30 | NT$102.38 | NT$481.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BORA PHARMACEUTICALS LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 30.61%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.47%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 3.54x
- Recent ROE (30.61%) is above the historical average (26.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 18.44% | 19.95% | 0.45x | 2.05x | NT$139.66 Million |
| 2020 | 23.47% | 32.14% | 0.26x | 2.84x | NT$331.95 Million |
| 2021 | 23.78% | 15.30% | 0.66x | 2.34x | NT$434.48 Million |
| 2022 | 30.74% | 13.26% | 0.46x | 5.03x | NT$939.08 Million |
| 2023 | 33.35% | 21.34% | 0.57x | 2.76x | NT$2.12 Billion |
| 2024 | 30.61% | 20.47% | 0.42x | 3.54x | NT$2.65 Billion |
Industry Comparison
This section compares BORA PHARMACEUTICALS LTD's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BORA PHARMACEUTICALS LTD (6472) | NT$15.69 Billion | 18.44% | 1.79x | $1.04 Billion |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |